PolyQ disease: Misfiring of a developmental cell death program?

Trends in Cell Biology

Volumn 23, Issue 4, 2013, Pages 168-174

  Blum, Elyse S ^a   Schwendeman, Andrew R ^a   Shaham, Shai ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ATAXIN 1; ATAXIN 2; ATAXIN 3; ATAXIN 7; ATROPHIN 1; BIOLOGICAL MARKER; CACNA1A PROTEIN; HUNTINGTIN; POLYGLUTAMINE; TATA BINDING PROTEIN; UNCLASSIFIED DRUG; PEPTIDE;

CELL DEATH; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE REPEAT; POLYGLUTAMINE DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MOTIF; REVIEW; SPINOCEREBELLAR DEGENERATION; AGING; ANIMAL; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; PATHOLOGY; TRINUCLEOTIDE REPEAT;

CAENORHABDITIS ELEGANS;

AGING; ANIMALS; CELL DEATH; GROWTH AND DEVELOPMENT; HUMANS; NEURODEGENERATIVE DISEASES; PEPTIDES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84883541737     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2012.11.003     Document Type: Review

References (97)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983
2. La Spada, A.R. et al. (1991) Androgen receptor gene mutations in Xlinked spinal and bulbar muscular atrophy. Nature 352, 77-79
3. Sequeiros, J. et al. (2010) Consensus and controversies in best practices for molecular genetic testing of spinocerebellar ataxias. Eur. J. Hum. Genet. 18, 1188-1195
4. Nolte, D. et al. (2010) Spinocerebellar ataxia type 17 associated with an expansion of 42 glutamine residues in TATA-box binding protein gene. J. Neurol. Neurosurg. Psychiatry 81, 1396-1399
5. Padiath, Q.S. et al. (2005) Identification of a novel 45 repeat unstable allele associated with a disease phenotype at the MJD1/SCA3 locus. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 133, 124-126
6. La Spada, A. (2011) Spinal and bulbar muscular atrophy. In GeneReviews (Internet) (Pagon, R.A. et al., eds), University of Washington (http://www.ncbi.nlm.nih.gov/books/NBK1333/)
7. Zoghbi, H.Y. and Orr, H.T. (2000) Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247
8. Wilburn, B. et al. (2011) An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. Neuron 70, 427-440
9. Orr, H.T. and Zoghbi, H.Y. (2007) Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575-621
10. Blum, E.S. et al. (2012) Control of nonapoptotic developmental cell death in Caenorhabditis elegans by a polyglutamine-repeat protein. Science 335, 970-973
11. Kimble, J. and Hirsh, D. (1979) The postembryonic cell lineages of the hermaphrodite and male gonads in Caenorhabditis elegans. Dev. Biol. 70, 396-417
12. Sulston, J.E. et al. (1980) The Caenorhabditis elegans male: postembryonic development of nongonadal structures. Dev. Biol. 78, 542-576
13. Abraham, M.C. et al. (2007) A morphologically conserved nonapoptotic program promotes linker cell death in Caenorhabditis elegans. Dev. Cell 12, 73-86
14. Ellis, H.M. and Horvitz, H.R. (1986) Genetic control of programmed cell death in the nematode C. elegans. Cell 44, 817-829
15. Pilar, G. and Landmesser, L. (1976) Ultrastructural differences during embryonic cell death in normal and peripherally deprived ciliary ganglia. J. Cell Biol. 68, 339-356
16. Chu-Wang, I.W. and Oppenheim, R.W. (1978) Cell death of motoneurons in the chick embryo spinal cord. I. A light and electron microscopic study of naturally occurring and induced cell loss during development. J. Comp. Neurol. 177, 33-57
17. Oppenheim, R.W. et al. (2001) Programmed cell death of developing mammalian neurons after genetic deletion of caspases. J. Neurosci. 21, 4752-4760
18. Bots, G.T. and Bruyn, G.W. (1981) Neuropathological changes of the nucleus accumbens in Huntington's chorea. Acta Neuropathol. 55, 21-22
19. Davies, S.W. et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548
20. Takahashi, H. et al. (2001) Neuronal nuclear alterations in dentatorubralpallidoluysian atrophy: ultrastructural and morphometric studies of the cerebellar granule cells. Brain Res. 919, 12-19
21. Zander, C. et al. (2001) Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3. Hum. Mol. Genet. 10, 2569-2579
22. Orr, H.T. (2012) The cell biology of disease: cell biology of spinocerebellar ataxia. J. Cell Biol. 197, 167-177
23. Mangiarini, L. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506
24. Brignull, H.R. et al. (2006) Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan-neuronal Caenorhabditis elegans model. J. Neurosci. 26, 7597-7606
25. Jackson, G.R. et al. (1998) Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21, 633-642
26. Warrick, J.M. et al. (1998) Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93, 939-949
27. Wellington, C.L. et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273, 9158-9167
28. Landles, C. et al. (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem. 285, 8808-8823
29. Nucifora, L.G. et al. (2012) Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J. Biol. Chem. 287, 16017-16028
30. Legleiter, J. et al. (2010) Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J. Biol. Chem. 285, 14777-14790
31. Waldron-Roby, E. et al. (2012) Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J. Neurosci. 32, 183-193
32. Tebbenkamp, A.T.N. et al. (2011) Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum. Mol. Genet. 20, 2770-2782
33. Juenemann, K. et al. (2011) Modulation of mutant huntingtin Nterminal cleavage and its effect on aggregation and cell death. Neurotox. Res. 20, 120-133
34. Miller, J.P. et al. (2010) Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 67, 199-212
35. Graham, R.K. et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125, 1179-1191
36. Gafni, J. et al. (2012) Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J. Neurosci. 32, 7454-7465
37. Ellerby, L.M. et al. (1999) Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J. Biol. Chem. 274, 8730-8736
38. Suzuki, Y. et al. (2010) Proteolytic processing regulates pathological accumulation in dentatorubral-pallidoluysian atrophy. FEBS J. 277, 4873-4887
39. Goti, D. et al. (2004) A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J. Neurosci. 24, 10266-10279
40. Colomer Gould, V.F. et al. (2007) A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiol. Dis. 27, 362-369
41. Jung, J. et al. (2009) Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum. Mol. Genet. 18, 4843-4852
42. Young, J.E. et al. (2007) Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J. Biol. Chem. 282, 30150-30160
43. Ellerby, L.M. et al. (1999) Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J. Neurochem. 72, 185-195
44. Tadokoro, K. et al. (2005) Frequent occurrence of protein isoforms with or without a single amino acid residue by subtle alternative splicing: the case of Gln in DRPLA affects subcellular localization of the products. J. Hum. Genet. 50, 382-394
45. Tsunemi, T. et al. (2008) Cell-type-specific alternative splicing in spinocerebellar ataxia type 6. Neurosci. Lett. 447, 78-81
46. Harris, G.M. et al. (2010) Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. PLoS ONE 5, e13695
47. Bettencourt, C. et al. (2010) Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3). Neurogenetics 11, 193-202
48. Parry, D.A.D. et al. (2008) Fifty years of coiled-coils and alpha-helical bundles: a close relationship between sequence and structure. J. Struct. Biol. 163, 258-269
49. Takahashi, T. et al. (2007) Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum. Mol. Genet. 17, 345-356
50. Arrasate, M. et al. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810
51. Perutz, M.F. et al. (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 91, 5355-5358
52. Ignatova, Z. et al. (2007) In-cell aggregation of a polyglutaminecontaining chimera is a multistep process initiated by the flanking sequence. J. Biol. Chem. 282, 36736-36743
53. Tanaka, M. et al. (2001) Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J. Biol. Chem. 276, 45470-45475
54. Thakur, A.K. et al. (2009) Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 16, 380-389
55. Fiumara, F. et al. (2010) Essential role of coiled coils for aggregation and activity of Q/N-Rich prions and PolyQ proteins. Cell 143, 1121-1135
56. Takahashi, T. et al. (2010) Polyglutamine diseases: where does toxicity come from? What is toxicity? Where are we going? J. Mol. Cell Biol. 2, 180-191
57. Arango, M. et al. (2006) CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J. Neurosci. 26, 4649-4659
58. Walters, R.H. and Murphy, R.M. (2011) Aggregation kinetics of interrupted polyglutamine peptides. J. Mol. Biol. 412, 505-519
59. Sen, S. et al. (2003) Role of histidine interruption in mitigating the pathological effects of long polyglutamine stretches in SCA1: a molecular approach. Protein Sci. 12, 953-962
60. Jayaraman, M. et al. (2009) The impact of ataxin-1-like histidine insertions on polyglutamine aggregation. Protein Eng. Des. Sel. 22, 469-478
61. Neumann, M. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133
62. Pesiridis, G.S. et al. (2009) Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum. Mol. Genet. 18, R156-R162
63. Fuentealba, R.A. et al. (2010) Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J. Biol. Chem. 285, 26304-26314
64. Santoso, A. et al. (2000) Molecular basis of a yeast prion species barrier. Cell 100, 277-288
65. Sondheimer, N. and Lindquist, S. (2000) Rnq1: an epigenetic modifier of protein function in yeast. Mol. Cell 5, 163-172
66. Michelitsch, M.D. and Weissman, J.S. (2000) A census of glutamine/ asparagine-rich regions: implications for their conserved function and the prediction of novel prions. Proc. Natl. Acad. Sci. U.S.A. 97, 11910-11915
67. Elden, A.C. et al. (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069-1075
68. Robertson, A.L. and Bottomley, S.P. (2010) Towards the treatment of polyglutamine diseases: the modulatory role of protein context. Curr. Med. Chem. 17, 3058-3068
69. Scarafone, N. et al. (2012) Amyloid-like fibril formation by polyQ proteins: a critical balance between the polyQ length and the constraints imposed by the host protein. PLoS ONE 7, e31253
70. Bhattacharyya, A. et al. (2006) Oligoproline effects on polyglutamine conformation and aggregation. J. Mol. Biol. 355, 524-535
71. Jeong, H. et al. (2009) Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137, 60-72
72. Mookerjee, S. et al. (2009) Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment. J. Neurosci. 29, 15134-15144
73. Aiken, C.T. et al. (2009) Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J. Biol. Chem. 284, 29427-29436
74. Gu, X. et al. (2009) Serines 13 and 16 are critical determinants of fulllength human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64, 828-840
75. Thompson, L.M. et al. (2009) IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 187, 1083-1099
76. Duvick, L. et al. (2010) SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776. Neuron 67, 929-935
77. Lim, J. et al. (2008) Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452, 713-718
78. Katsuno, M. et al. (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843-854
79. Takeyama, K-I. et al. (2002) Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35, 855-864
80. Nedelsky, N.B. et al. (2010) Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 67, 936-952
81. Monks, D.A. et al. (2007) Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc. Natl. Acad. Sci. U.S.A. 104, 18259-18264
82. Aronin, N. et al. (1995) CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain. Neuron 15, 1193-1201
83. Servadio, A. et al. (1995) Expression analysis of the ataxin-1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals. Nat. Genet. 10, 94-98
84. Imbert, G. et al. (1996) Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 14, 285-291
85. Colby, D.W. et al. (2006) Stochastic kinetics of intracellular huntingtin aggregate formation. Nat. Chem. Biol. 2, 319-323
86. Subramaniam, S. et al. (2009) Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 324, 1327-1330
87. Falk, J.D. et al. (1999) Rhes: a striatal-specific Ras homolog related to Dexras1. J. Neurosci. Res. 57, 782-788
88. Havel, L.S. et al. (2011) Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum. Mol. Genet. 20, 1424-1437
89. Van Raamsdonk, J.M. et al. (2005) Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14, 3823-3835
90. Koch, P. et al. (2011) Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 480, 543-546
91. Vernace, V.A. et al. (2007) Aging and regulated protein degradation: who has the UPPer hand? Aging Cell 6, 599-606
92. Morley, J.F. et al. (2002) The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 99, 10417-10422
93. Ben-Zvi, A. et al. (2009) Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc. Natl. Acad. Sci. U.S.A. 106, 14914-14919
94. Osterloh, J.M. et al. (2012) dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science 337, 481-484
95. Fuchs, M. et al. (2001) The p400 complex is an essential E1A transformation target. Cell 106, 297-307
96. Makinen, N. et al. (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334, 252-255
97. Lim, J. et al. (2006) A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 125, 801-814